Salute e Benessere

XNK Therapeutics to present at Investival Showcase Meeting

The presentation is followed by a short Q&A session. The presentation is followed by a short Q&A session. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail:johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy...

SciBase: Interim report

The third quarter in figures: The third quarter in figures: January - September in figures Important events during the quarter Important events after the end of the period Financial overview This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onNovember 10, 2023. This report has been...

Novo Nordisk invests more than 42 billion Danish kroner in expansion of…

Bagsværd, Denmark, 10 November 2023– Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 2023 1to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases. The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where more than 23,000 employees still work today. Most of these employees work at production sites.The investment...

One-GN transformation well on track. Hearing continued strong organic growth…

- - GN Store Nord GN delivered continued focused execution across the company resulting in 1% revenue growth compared to Q2 2023. Group organic revenue growth was 0%Adj. EBITA was DKK 495 million, equal to an adj. EBITA margin improvement of 1.9 percentage points compared to Q2 2023 (0.6 percentage points lower than Q3 2022), driven by tightly managed OPEX. This led to strong free cash flow excl. M&A of DKK 279 million and in combination with the disposal of BelAudição, the net...

Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine…

Saint-Herblain (France), November 10, 2023–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has approved IXCHIQ ®, Valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. This indication is approved under accelerated approval based on...

New documentary highlights pioneering scientific research into new targets for…

New documentary highlights pioneering scientific research into new targets for treatment of motor neuron disease10 November 2023– A new documentary has been released which follows a key discovery made by researchers at University College London that suggests a promising target for new treatments to tackle motor neuron disease (MND), a terminal condition.Backed by MND charities and the MND scientific community, including medical research charity, LifeArc, the short-documentary...

Navigating the Complex Market Landscape of Rare Genetic Disorders: A Deep Dive…

DelveInsight has recently released a series of epidemiology-based market reports focusing on rare genetic disorders including Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AA1TD). These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into 7MM [the United…

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label…

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in ToddlersViaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444 mg without meeting...

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on…

Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET PARIS and CAMBRIDGE, Mass., Nov.09, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial results for the third quarter ended September 30, 2023, on Monday,...

GENFIT Reports Third Quarter 2023 Financial Information

Cash and cash equivalents totaled €93.9 million as of September 30, 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2023 and revenue for the first nine months of 2023 1. Cash Position As of September 30,...

ResMed Adopts New Operating Model to Accelerate Long-term Growth

Justin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective immediately.Rob Douglas, President and Chief Operating Officer, to retire January 1, 2024.SAN DIEGO, Nov.09, 2023(GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated...

Disclosure of notification received from BNP Paribas Asset Management SA

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 November 2023 – 6PM CET Disclosure of notification received from BNP Paribas Asset Management SA Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from BNP Paribas Asset Management SA. Notification of BNP Paribas Asset Management SAOn 8 November 2023, Fagron received a notification that the shareholding of BNP Paribas Asset...

Addressing radiology workload challenges: Sectra and GE HealthCare plan to…

With cardiology being one of the most demanding clinical workflow environments, this integration would begin with a focus on the cardiology care pathway and GE HealthCare's CardIQ Suite, a workflow which leverages Deep Learning to automatically identify the presence and location of coronary artery calcifications and provide a total and per territory score within seconds of loading. When combined with Sectra's diagnostic application, clinicians could enhance CardIQ Suite's efficiency, potentially…

Ultimovacs ASA: Share capital increase related to exercise of options

The new shares are issued to employees of the Company in connection with the Company's employee incentive program. The new shares are issued at a subscription price of NOK 31.25.Following registration of the share capital increase with the Norwegian Register of Business Enterprises, the Company will have a share capital of NOK 3,440,606.10, divided into 34,406,061 shares, each with a par value of NOK 0.10.For further information, please contact: Jónas Einarsson, Chairman of the Board...

Novartis data show potential of remibrutinib as an oral treatment for chronic…

In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton's tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo 1 Treatment with remibrutinib led to significant improvement in symptom control, as early as Week 2 and sustained up to Week 12 1 Remibrutinib was well-tolerated and demonstrated a favorable safety profile with rates of overall adverse events comparable to placebo...

Cellular Health Screening/Health Testing Market size worth $ 6.08 Billion…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24033 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24033 Browse in-depth TOCon" Cellular Health Screening/Health Testing Market " 202 - Pages 126 – Tables 37 – Figures Unlocking the Future of Health: Breakthroughs in Cellular Health Screening/Health Testing Market Innovative Solutions and Pioneering Players Propel the Industry Forward The...

Particle Therapy Market Worth $1.1 Billion | MarketsandMarkets

Browse in-depth TOC on "Particle Therapy Market" 168 - Tables 55 - Figures 225 - Pages Browse in-depth TOC on "Particle Therapy Market"168 - Tables55 - Figures225 - Pages Particle Therapy Market Scope: The treatment application includes different application segments, The Paediatric application segment showed a significant share of the Particle therapy market in 2022-2027. Based on the cancer types, the particle therapy market is segmented into pediatric cancer,...

Essential Oils Market size worth $ 38.30 Billion, Globally, by 2030 at 7.43%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=3519 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=3519 Browse in-depth TOCon" Essential Oils Market " 202 - Pages 126 – Tables 37 – Figures Essential Oils Market: A Thriving Industry Steered by Innovation and Global Demand Verified Market Research®, a leading authority in market research, presents a comprehensive analysis of the Essential Oils...

Suki AI Wins 2023 North American Frost & Sullivan Entrepreneurial Company of the…

Each year, Frost & Sullivan honors the most promising and disruptive market participant with the award. Suki AI stands out with its innovative use of technology and quick response to market needs that bring forth groundbreaking solutions and redefine the competitive landscape. Each year, Frost & Sullivan honors the most promising and disruptive market participant with the award. Suki AI stands out with its innovative use of technology and quick response to market needs that bring…

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 9, 2023 –Genmab A/S(Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of November 8, 2023, Wellington Management Group LLP through shares and financial instruments held the voting rights to 3,300,545 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights...

Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as…

Oncolytics Biotech® Inc.(NASDAQ: ONCY) (TSX: ONC): Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy - Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response - Oncolytics Biotech® Inc., a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results…

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host aconference call and webcastto discuss the Company's Q3 2023 operational and financial results on Wednesday, November 15, 2023 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing...

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer…

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio NVIDIAandBayer, and a new collaboration withTempus Labsas it creates infrastructure and expands its ambitions and scope in the precision oncology space. “Since our founding we have believed that the next generation of biopharma leaders would operate at the intersection of scaled datasets and accelerated computing,”...

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of…

"The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers. These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "I am especially pleased to note that this…

Altri Comunicati